This section of ELAPRASE.com is intended for U.S. healthcare professionals. Click here for the patients and families section.

Elaprase

About ELAPRASE (idursulfase)

ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II). ELAPRASE has been shown to improve walking capacity in patients 5 years and older.

In patients 16 months to 5 years of age, no data are available to demonstrate improvement in disease-related symptoms or long term clinical outcome; however, treatment with ELAPRASE has reduced spleen volume similarly to that of adults and children 5 years of age and older.

The safety and efficacy of ELAPRASE have not been established in pediatric patients less than 16 months of age.

ELAPRASE is the only FDA-approved enzyme replacement therapy (ERT) for MPS II

  • ELAPRASE is indicated for patients with Hunter syndrome (Mucopolysaccharidosis II, MPS II).
  • ELAPRASE has been shown to improve walking capacity in patients 5 years and older.
  • ELAPRASE is a purified form of human iduronate-2-sulfatase, a lysosomal enzyme; it is produced by recombinant DNA technology in a human cell line.
  • ELAPRASE is intended to provide exogenous enzyme for uptake into cellular lysosomes to catabolize accumulated GAGs.
  • The recommended dosage regimen is 0.5 mg per kg of body weight administered once weekly as an intravenous infusion. Learn about dosing.

> ELAPRASE Full Prescribing information